Relaxin in cardiovascular and renal disease.
Relaxin in cardiovascular and renal disease.
复制标题
心血管和肾脏疾病中的松弛素。
作者：
C. Samuel;T. Hewitson
纤维化（器官瘢痕形成）是许多形式的心血管和肾脏疾病的标志，并且当正常组织被瘢痕组织替代时引起器官功能障碍和结构变化;瘢痕组织的积累是世界各地死亡的主要原因。尽管深部器官瘢痕可能以多种形式存在（包括心肌和血管硬化、肾间质纤维化和肾小球硬化），但目前的治疗在延迟终末期疾病方面仅取得有限的成功。肽激素松弛素正在成为一种有效的抗纤维化治疗与快速发生的疗效。最近的研究已经证明了松弛素在体内心脏和肾脏疾病的实验模型中的抗纤维化作用，以及松弛素在体外抑制成纤维细胞诱导的胶原过度产生导致纤维化的各种水平。使用松弛素基因敲除小鼠的单独研究已经证明了内源性松弛素作为胶原蛋白周转的天然存在和保护性调节剂的重要性，而松弛素的治疗潜力已经通过其促进血管舒张和肾超滤的能力而增强。这篇综述将总结这些一致的发现，作为强调松弛素在心血管和肾脏疾病中的临床潜力的一种手段。
Fibrosis (organ scarring) is a hallmark of many forms of cardiovascular and renal disease, and causes organ dysfunction and structural changes when normal tissue is replaced with scar tissue; the accumulation of scar tissue being a leading cause of death around the world. Despite deep organ scarring potentially existing in many forms (including myocardial and vascular sclerosis, renal interstitial fibrosis, and glomerulosclerosis), current therapies have only had limited success in delaying end-stage disease. The peptide hormone relaxin is emerging as a potent antifibrotic therapy with rapid-occurring efficacy. Recent studies have demonstrated the antifibrotic actions of relaxin in experimental models of cardiac and renal disease in vivo, and the various levels at which relaxin acts to inhibit fibroblast-induced collagen overproduction leading to fibrosis, in vitro. Separate studies using relaxin gene-knockout mice have demonstrated the significance of endogenous relaxin as a naturally occurring and protective moderator of collagen turnover, while the therapeutic potential of relaxin has been enhanced by its ability to promote vasodilation and renal hyperfiltration. This review will summarize these coherent findings as a means of highlighting the clinical potential of relaxin in cardiovascular and renal disease.
影响因子：
15.9
作者：
Novak, J;Danielson, LA;Conrad, KP
通讯作者：
Conrad, KP